References of "Denis, D"
     in
Bookmark and Share    
See detailHuntingtin mediates anxiety/depression-related behaviors and hippocampal neurogenesis.
M'Barek, K. Ben; Orvoen, S.; Pla, P. et al

Poster (2012)

Detailed reference viewed: 6 (0 ULg)
See detailLes indicateurs de l'OCDE 2004.
Barthélémy, D.; Jauniaux, N.; Denis, D. et al

Book published by Ministère de la Communauté française, Secrétariat général, Direction des Relations internationales (2006)

Detailed reference viewed: 5 (0 ULg)
See detailClés de lecture de Regards sur l'Education n° 8 : les indicateurs de l'OCDE
Barthélémy, D.; Baye, Ariane ULg; Blondin, Christiane ULg et al

Book published by Ministère de la Communauté Française, Direction des Relations Internationales (2005)

Detailed reference viewed: 17 (1 ULg)
See detailClés de lecture de Regards de l'Education n° 7 : les indicateurs de l'OCDE
Barthélémy, D.; Baye, Ariane ULg; Blondin, Christiane ULg et al

Book published by Ministère de la Communauté Française, Direction des Relations Internationales (2004)

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailPrévention de l’ostéoporose à Liège. Histoire d’un PIGEPS : dix ans plus tard.
Reginster, Jean-Yves ULg; DEROISY, Rita ULg; LECART, Marie-Paule ULg et al

in Santé Publique : Revue Multidisciplinaire pour la Recherche et l'Action (1996), 2

Detailed reference viewed: 17 (3 ULg)
Full Text
Peer Reviewed
See detailLong-Term (3 Years) Prevention of Trabecular Postmenopausal Bone Loss with Low-Dose Intermittent Nasal Salmon Calcitonin
Reginster, Jean-Yves ULg; Denis, D.; Deroisy, Rita ULg et al

in Journal of Bone and Mineral Research : The Official Journal of the American Society for Bone and Mineral Research (1994), 9(1), 69-73

The long-term effect of intermittent low-dose nasal salmon calcitonin on trabecular early postmenopausal bone loss was assessed as follow-up to a previously published study. Randomized controlled group ... [more ▼]

The long-term effect of intermittent low-dose nasal salmon calcitonin on trabecular early postmenopausal bone loss was assessed as follow-up to a previously published study. Randomized controlled group comparison was made of 287 healthy women with 6-36 months of natural menopause and no treatment interfering with calcium metabolism at an outpatient clinic for research in bone and cartilage metabolism. The 287 women were randomly allocated to 3 years of treatment with either 500 mg/day, 5 days/week of calcium or the same amount of calcium plus 50 IU/day, 5 days per week of nasal salmon calcitonin. A total of 186 women complied with the study protocol throughout. The main outcome measures were bone mineral density of the lumbar spine (DPA) and biochemical parameters reflecting bone turnover (serum alkaline phosphatases, urinary calcium/creatinine, and hydroxyproline/creatinine ratio). The average changes in bone mineral density after 36 months showed a positive (p < 0.05) outcome (1.8 +/- 5.7%; mean +/- SD) in the group treated with salmon calcitonin and calcium and a significant (p < 0.01) loss (-5.8 +/- 4.8%) in patients receiving calcium alone. The difference between the evolution of the two groups was significantly (p < 0.01) different after 6 months of treatment and remained so until the end of the study. No significant changes were recorded in biochemical parameters reflecting bone turnover. As previously shown during a 1 year follow-up, nasal salmon calcitonin given at low dose and intermittently, in association with calcium, can counteract trabecular postmenopausal bone loss. [less ▲]

Detailed reference viewed: 9 (1 ULg)
Peer Reviewed
See detailAcute biochemical variations induced by four different calcium salts in healthy male volunteers
Reginster, Jean-Yves ULg; Denis, D; Bartsch, V et al

in Equilibre (1994), 19

Detailed reference viewed: 15 (2 ULg)
Full Text
Peer Reviewed
See detailAcute Biochemical Variations Induced by Four Different Calcium Salts in Healthy Male Volunteers
Reginster, Jean-Yves ULg; Denis, D.; Bartsch, Valérie ULg et al

in Osteoporosis International : A Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis & the National Osteoporosis Foundation of the USA (1993), 3

Calcium (Ca) supplements have positive effects in growing children, reduce bone loss in late-postmenopausal women with a low calcium diet and, in association with vitamin D3 supplements, may reduce non ... [more ▼]

Calcium (Ca) supplements have positive effects in growing children, reduce bone loss in late-postmenopausal women with a low calcium diet and, in association with vitamin D3 supplements, may reduce non-vertebral fracture rates in elderly women. However, for many formulated pharmaceutical products their relative beneficial effects have not been conclusively established. We have compared the acute (6 h) metabolic responses following oral administration of two preparations of calcium gluconolactate and carbonate (CG and CG'), tricalcium phosphate (TCP) and calcium citrate (CC), given on separate occasions in each of 10 healthy young male volunteers. The subjects fasted overnight for 12 h and continued to fast during the experimental procedure. A 1000 mg dose of each Ca salt was ingested at weekly intervals. Blood was drawn after 30, 60, 90, 120, 180, 240, 300 and 360 min for measurement of serum Ca, phosphorus (P), parathyroid hormone (PTH) and whole plasma calcitonin (iCT). All Ca supplements induced significant (+6.4% to +8.1%; p < 0.01) increases in Ca and significant suppression of PTH (-37.4% to -57.4%; p < 0.01). Comparison of response curves revealed significantly (p < 0.01) more marked Ca increase and PTH suppression with CC than with the other three Ca salts. CG' and CC induced marginal decreases in serum P and the overall curve of P variations was different for TCP compared with CG, CG' and CC. No significant variation of iCT was recorded during the test.(ABSTRACT TRUNCATED AT 250 WORDS) [less ▲]

Detailed reference viewed: 16 (6 ULg)
Peer Reviewed
See detailLong term (3 years) prevention of trabecular postmenopausal bone loss with low dose intermittent nasal salmon calcitonin
Reginster, Jean-Yves ULg; DEROISY, Rita ULg; Albert, Adelin ULg et al

in Revue du Rhumatisme et des Maladies Osteo-Articulaires (1992), 59

Detailed reference viewed: 6 (2 ULg)
Peer Reviewed
See detailComparison of acute biochemical variations induced by ingestion of different calcium salts in healthy volunteers
Reginster, Jean-Yves ULg; Denis, D; Bartsch, Valérie ULg et al

in Revue du Rhumatisme et des Maladies Osteo-Articulaires (1992), 59

Detailed reference viewed: 14 (2 ULg)
Peer Reviewed
See detailIntérêts et limites de l'absorptiométrie biphotonique dans le dépistage de l'ostéoporose postménopausique
Reginster, Jean-Yves ULg; DEROISY, Rita ULg; Zegels, Brigitte ULg et al

in Revue du Rhumatisme et des Maladies Osteo-Articulaires (1992), 59

Detailed reference viewed: 14 (3 ULg)
Full Text
Peer Reviewed
See detailDual Photon Absorptiometry of Lumbar Spine in West European (Belgian) Postmenopausal Females: Normal Range and Fracture Threshold
Reginster, Jean-Yves ULg; Denis, D.; Deroisy, Rita ULg et al

in Clinical Rheumatology (1990), 9(2), 220-4

Bone mineral content (BMC) and bone mineral density (BMD) of lumbar spine have been measured in 695 healthy postmenopausal and 64 type I osteoporotic Belgian, Caucasian females. Bone loss is strongly ... [more ▼]

Bone mineral content (BMC) and bone mineral density (BMD) of lumbar spine have been measured in 695 healthy postmenopausal and 64 type I osteoporotic Belgian, Caucasian females. Bone loss is strongly correlated to time elapse from menopause (Tm) with a maximum rate of bone loss during the first five years of menopause. BMC (gHA) = 461 + 0.662 ln Tm -0.481 (ln Tm)2 and BMD (gHA/cm2) = 0.91 + 0.00711 ln Tm - 0.00846 (ln Tm)2 (in both cases p less than 0.001 and Tm expressed in months of menopause). After 20 years of menopause, 50 to 60% of normal women have vertebral BMC and BMD values below the 90th percentile of women with vertebral fractures and, thus, might be considered to have asymptomatic osteoporosis. We conclude that prevention of postmenopausal osteoporosis should be initiated as soon as possible after the onset of menopause and that bone density screening should be extended in elderly in order to detect and allow treatment of asymptomatic "densitometric" osteoporosis. [less ▲]

Detailed reference viewed: 16 (3 ULg)
Peer Reviewed
See detailPrevention of postmenopausal bone loss by tiludronate
Reginster, Jean-Yves ULg; Lecart, MP; DEROISY, Rita ULg et al

in Menopause Digest (1990), 4

Detailed reference viewed: 13 (2 ULg)
Full Text
Peer Reviewed
See detailInfluence of Specific Anti-Salmon Calcitonin Antibodies on Biological Effectiveness of Nasal Salmon Calcitonin in Paget's Disease of Bone
Reginster, Jean-Yves ULg; Gennari, C.; Mautalen, C. et al

in Scandinavian Journal of Rheumatology (1990), 19(1), 83-6

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailIn Vivo Long-Term Precision of Spinal Bone Mass Measurement by Dual Photon Absorptiometry
Reginster, Jean-Yves ULg; Geusens, P.; Nijs, J. et al

in Bone and Mineral (1989), 6(2), 225-9

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailRelationship between Whole Plasma Calcitonin Levels, Calcitonin Secretory Capacity, and Plasma Levels of Estrone in Healthy Women and Postmenopausal Osteoporotics
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Albert, Adelin ULg et al

in Journal of Clinical Investigation (1989), 83(3), 1073-7

The exact role of calcitonin (CT) in the pathogenesis of postmenopausal osteoporosis remains unknown. Whole plasma calcitonin (iCT) basal levels, metabolic clearance rate (MCR), and production rate (PR ... [more ▼]

The exact role of calcitonin (CT) in the pathogenesis of postmenopausal osteoporosis remains unknown. Whole plasma calcitonin (iCT) basal levels, metabolic clearance rate (MCR), and production rate (PR) of CT were measured in 9 premenopausal and 16 postmenopausal women, including 11 osteoporotics (OP). Basal iCT levels were statistically lower in postmenopausal women than in the premenopausal group (P less than 0.01) and strongly correlated (r = 0.72; P less than 0.001) with estrone circulating levels (E1). MCR were similar in all groups. PR were similar in eugonadal women between 22 (mean +/- SD = 30.9 +/- 9.9 micrograms/d) and 37 yr (mean +/- SD = 25.5 +/- 11.1 micrograms/d) premenopausal women. In healthy postmenopausal women PR were reduced, but not significantly (mean +/- SD = 19.5 +/- 6.95 micrograms/d), whereas osteoporotic patients presented a highly significant reduction of CT PR (mean +/- SD = 9.8 +/- 4 micrograms/d) (P less than 0.01). Because there is a strong relationship between E1 and PR (r = 0.64; P less than 0.001), CT secretory capacity appears to be modulated by estrogen circulating levels. This modulation leads to a menopause-related decrease in iCT. In osteoporotics, an independent impairment of CT production drastically lowers PR and basal iCT levels. CT might be one of the determining factors in the pathogenesis of postmenopausal osteoporosis. [less ▲]

Detailed reference viewed: 10 (3 ULg)
Peer Reviewed
See detailSalmon calcitonin: state of the art in prevention of postmenopausal bone loss
Reginster, Jean-Yves ULg; DEROISY, Rita ULg; Denis, D et al

in Journal Belge de Médecine Physique et de Réhabilitation = Belgisch Tijdschrift voor Fysische Geneeskunde en Rehabilitatie (1989), 12

Detailed reference viewed: 5 (2 ULg)
Peer Reviewed
See detailCalcitonin for prevention of postmenopausal bone loss: rational and results
Reginster, Jean-Yves ULg; DEROISY, Rita ULg; Denis, D et al

in European Journal of Clinical Investigation (1989), 19

Detailed reference viewed: 11 (5 ULg)